



Life Science Cluster, Tenancy, and Property Age to Telegraph Trouble

We expect to see some distress in life science exposures, before the sector likely turns a corner in 2026. Life science properties are facing both supply and demand headwinds. Oversupply and rising vacant sublease space are driving higher vacancies and softer market rents. Tenant demand has been sluggish. But the construction pipeline is dramatically dropping. Of the 16 million square feet under construction, 87.5% will be delivered this year, leaving only two million square feet deliveries beyond 2025. The under-construction pipeline has already dropped to 7% of total inventory in Q4 2024, down from 17% in Q2 2023. Tenant demand may also improve amid record life science employment, and a robust pipeline of new drug development. But we believe the demand side is a bit trickier to project considering policies of the new administration.

Stav Gaon
+1 (646) 768-9173
sgaon@academysecurities.com

Headquarters Address:
Academy Securities, Inc.
622 Third Avenue, 12th Fl
New York, NY 10017

CMBS life science loans have not yet fully reflected the sector’s softer fundamentals. We do not see notable delinquencies or specially serviced situations. But some loans clearly have seen their parameters deteriorating. Borrowers may struggle to make debt payments down the road if the specific properties continue slipping. Examples include the \$2.87 billion Biomed Pool A (LIFE 2022-BMR2) and the \$415 million Genesis Towers (VLS 2020-LAB). The underlying portfolios of both loans had sharp occupancy drops, from the high 90s at issuance, to low 70s as of last reporting (Figure 1). In Biomed Pool A, DSCR is near a breaking point, at 1.0x. The Biomed borrower just exercised a one-year extension option, according to fresh servicer commentary. In turn, Genesis only matures in October 2030.

Figure 1. Life Sciences CMBS Parameters Soften

Deal	Current Balance (\$MM)	Payment Status	Most Recent				At Issuance		
			Occupancy	Net Cash Flow (\$MM)	DSCR	As-Of Date	Occupancy	Net Cash Flow (\$MM)	DSCR
LIFE 2022-BMR2	2,875.0	Performing	70.0%	209.1	1.00	Sep-2024	95.5%	238.4	3.11
CAMB 2019-LIFE	1,170.0	Performing	95.0%	134.1	1.49	Dec-2024	99.0%	94.9	1.76
LIFE 2021-BMR	713.1	Performing	92.0%	103.8	0.76	Sep-2024	97.1%	135.4	4.11
VLS 2020-LAB	415.0	Performing	72.0%	38.8	3.50	Sep-2024	94.3%	43.6	3.96
BX 2023-LIFE	400.0	Performing	67.0%	19.5	0.89	Sep-2024	100.0%	38.0	1.67
DBGS 2018-BIOD	308.9	Performing	65.0%	34.2	0.72	Sep-2024	89.2%	69.1	2.97

Source: Morningstar Credit and Academy Securities


Pros and Cons Across Life Science Properties

We see several aspects currently telegraphing trouble across specific life science exposures, along with potential mitigating factors:

- **Weakness acute at top life science markets...** Some of the key fundamental parameters strikingly differ across the various life science markets. The top-3 clusters – Boston-Cambridge, San Francisco Bay Area, and San Diego – recorded especially weak trends compared to other areas. For example, the top markets had 5.3 million sf negative absorption since 2023, according to CBRE. In contrast, the other 10 major markets had 1.9 million square feet positive net absorption over this period. Vacancy rates and rents have also been significantly weaker in the top markets (top-3 – 22% vacancy in Q3 2024; other primary markets - 12%).

CMBS loans have elevated exposure to the top-3 markets (Figure 2, left). Recently issued deals, such as the \$535 million BX 2025-BIO3, epitomize the exposure. BIO3’s underlying eight properties are all located in the top-3 markets. Some of the CMBS concentrated geographic exposure just reflects the dominance of the top markets in the life sciences sector, and the preference across some of the landlords in those markets for CMBS financing. Still, the relative fundamental weakness in the top markets could be pronounced in securitized properties.

Figure 2. CMBS Life Sciences Exposure by Clusters and Tenants



Source: Morningstar Credit and Academy Securities


- **...But clustering still beneficial in the sector.** Despite the fundamental challenges, the top markets appeal to life science tenants, the “clustering” benefits, could offset some of the weakness. The sector has seen some “de-clustering”, where new markets emerge as life science hubs. Examples include Indianapolis, IN, Phoenix, AZ, and major cities in Texas. But the de-clustering momentum in life sciences appears less powerful than in [data centers](#).¹ The proximity to top academic institutions and a pool of specialized life science labor, play a critical role in hub strength. In contrast, aspects such as power availability or zoning regulations, that more easily lend themselves to de-clustering, play a more significant role in the data centers sector.

¹ “Power Costs: Data Centers and Recovery Bonds Poised for More Predictability,” Securitized Products Special Topics, Academy Securities, March 10, 2025

Life Sciences: Surveil Your Exposure as Distress Percolates

- **Single tenancy especially concerning...** We see a high percentage of single-tenant properties in recent life science deals (Figure 2, right). For example, in BX 2025-BIO3, 78.3% of the properties in the portfolio are leased to a single tenant. One of the single tenants in the deal even went dark in August 2023 (the tenant is still performing on its lease, which expires in December 2027, according to deal documents). In TPG 2024-WLSC single tenant exposure is 38.3%. Of course, the concern over single-tenant properties is not unique to life sciences collateral. But given softer demand and specialized needs of life science tenants, it appears single-tenancy presents a particular concern for outstanding life science loans.
- **...But specialized spaces may mitigate single-tenancy risk.** Unique regulatory requirements, and the very specialized nature of lab spaces, may make some life science tenants “sticky”. The 7 Powder Horn Drive property (\$16.5 million, BBCMS 2020-C8) offers an interesting anecdote. The single-tenant property in Warren, NJ, received an FDA license for vein-to-vein biological production of immunotherapy treatments. Such licenses, which require many years to obtain, are not transferable between locations, according to deal documents. As such, this could reduce lease termination risk at the location, as long as the tenant needs the license. Such site-specific attributes echo “mission critical” or so-called “sciffed” buildings. Sensitive Compartmented Information Facility Use (SCIF) buildings face lower termination risks, as we previously [discussed](#).²
- **Old properties at risk...** Another familiar risk, property age, may also afflict life science properties. We see relatively old properties in a sector that may be especially prone to space obsolescence (Figure 3). For example, TPG 2024-WLSC features properties originally built in 1960 and 1961. The deal’s overall portfolio has an average year built of 1973.
- **...But frequent renovations may reduce obsolescence.** Deal documents emphasize repeated renovations of older properties. The 1960-built property in TPG 2024-WLSC, 225 Second Avenue in Waltham, MA, was renovated in 1999, 2018, and 2023. Still, such relatively frequent renovations underscore some of the challenges for investors who are not specialists in life sciences to assess property obsolescence. It is not clear why such renovations are needed, and what determines their ideal frequency. This again brings up a comparison to data centers, where investors may also grapple with assessing obsolescence in a rapidly changing sector.

Figure 3. CMBS Life Sciences Exposure by Property Age



Source: Morningstar Credit and Academy Securities

² “Government Tenants: Short Termination Notices and Specialized Properties,” CMBS Credit Focus, Academy Securities, March 22, 2022

Academy Securitized Products Research Recent Reports

Securitized Products Special Topics - Esoteric ABS:

[Power Costs: Data Centers and Recovery Bonds Poised for More Predicatability](#)

[Sports Securitization: Vet League Revenues and Stadium Cashflows](#)

[Timeshare ABS: Program-specific Attributes to Drive Performance](#)

[Music ABS: Pool Variations Emerge Amid Constructive Sector View](#)

[Tower ABS: Tenant Preferences Bode Well for Leasing Demand](#)

[Aircraft ABS: Momentum Builds for Insurance Booster](#)

[Data Centers: Tenant Rosters Poised to Change](#)

[Container ABS: Geopolitical Tailwinds as Issuance Picks Up](#)

[Gas Securitization: Shorter WAL Alternative to Electric Charge Deals](#)

[Net Leases: Scarcity Value as Issuance Poised to Pick Up](#)

[Recovery Bonds: Deal Reporting Shows True-Up Adjustments Potency](#)

[Data Centers: Performance Wrinkles to Test Operators' Role](#)

[Recovery Bonds: Diversifying Exposure Moves Beyond Disasters](#)

[Device Payment ABS: Expect Stable Performance as Collateral Evolves](#)

[Aircraft ABS: Waterfalls Playing Catch-Up as Fundamentals Recover](#)

[Data Centers: Teakeaways from 2023-Vintage Deals](#)

[Litigation ABS: Tailwinds in Place for an Uncorrelated Segment](#)

[Equipment ABS: Pick Your Spots Amid Diverging Collateral Trends](#)

[Commercial Solar ABS: Emergent Segment to Alleviate Headline Risks](#)

[Cell Towers: Lender-Friendly Features Dovetail with Secular Tailwinds](#)

[Timeshare ABS: Exposure to Favorable Hospitality Segments](#)

[Recovery Bonds: No Need to Closely Watch the Fed or the Economy Here](#)

[Data Centers: A Strong Segment Juggles ABS and CMBS](#)

Securitized Products Special Topics:

[CRE CLO Liquidations: Losses Accumulate, but No Immediate Writedowns](#)

[Office Contractions: New Term Rollover Risk, and Swelling Reserves](#)

[Multifamily Expenses: Broad Increases Mask the Fluctuations](#)

[Small Balance Commercial: Periphery Locations and “Weak” Sponsors May Prove Supportive](#)

[Investor Non-QM: Pockets of Value as Underwriting Tightens](#)

[Multifamily Prepays: Becoming Less Common, as Property Sales Drop](#)

[CRE CLO Mods: Rising Volume Not Immediately Telegraphing Distress](#)

[Agency Floaters: Adjusting Interest Rate Cap Escrows](#)

[Multifamily CRT: Limited Credit Risk on Synthetic Exposures](#)

[OC Triggers: Subtle Thresholds Come to the Fore As Collateral Stress Builds Up](#)

[Self Storage: Aspects to Watch as Performance Decelerates](#)

[Transitional Multifamily: Collateral Migration Away from CRE CLO Offers Different Deal Profile](#)

[Affordable Mortgages: Fee Elimination Spotlights Convexity Profile](#)

[Investor Non-QM: Rental Exposure with Some Structural Twists](#)

[Small Balance Multifamily: Value Ahead of Slow Prepays](#)

[Future Funding: Potential Key Performance Driver as CRE CLO Pipeline Builds Up](#)

[Multifamily Prepays: Property Sales Trigger Paydowns](#)

[Manufactured Housing: Resilient Segment Amid Potential Multifamily Softness](#)

[Tender Offers: Expect More to Come, Though Not on a Predictable Schedule](#)

[NYC Multifamily: Rent Increases to Support Cashflows Amid Regulatory Restrictions](#)

[Housing at a Crossroads: Single-family and Multifamily Exposures](#)

[Senior Housing: Focus on Segment Selection Amid Pandemic Impact](#)

[Disaster Performance: Pandemic Forbearance Resolutions Bode Well for Future Stresses](#)

[Russian Sanctions Impact: Lease Terminations and Forced Property Sales](#)

CMBS Credit Focus:

[Privileged Appraisals: Surprise ARA Jumps Baffle Investors](#)
[Office Re-defaults: Foreclosures to the Fore as Modified Maturities Near](#)
[Interest Adjustments: Track Shortfalls Repayment and Priority](#)
[New Leases: Track Post-Issuance Replacement Tenants](#)
[Property Protection Advances: Track Opaque Expenses in Long Workouts](#)
[Parkmerced: Abundance of Structural Angles to Determine Bond Cashflows](#)
[Pro-rata Prepays: Surprise Booster for Subordinate Bonds](#)
[PILOT: Check Another Wrinkle of Ground Leases](#)
[Non-Trust Debt: Check the Seniority of Your CMBS Collateral](#)
[Recovering Shortfalls: Credit IO Value in Distressed Office](#)
[Releasing Holdbacks: RENT is Writing Up Bonds](#)
[Reserves vs Advances: Servicers Tap Reserves to Lower Advances](#)
[Forward Forbearances: One Market Plaza Introduces a Twist to Mods](#)
[Loan Assumptions: Watch Waterfalls as New Borrowers Redevelop](#)
[Holdbacks: RENT in the Limelight, as Other Cases Brewing](#)
[Blanket NRAs: Shutting Down Advances Upends Credit IO Trades](#)
[Credit 2024: Workout Nuances Come to the Fore](#)
[Recovering the Non-Recoverable: Liquidation Nuance Bolsters Paydowns](#)
[Special Servicer Replacements: 1740 Broadway Crystalizes Implications](#)
[Crossgates Liquidation: Holdbacks Complicate Severity Projections](#)
[WODRA: Bond Cashflows Under Stress in Post-Mod Advance Recovery](#)
[Securitized Mezz: Workout Dynamics in Public Display](#)
[Dark Triggers: Nuances in Focus as Tenant Departures and Subleasing Pick Up](#)
[Upping Appraisals: Recovering Valuations Reverse Shortfalls](#)
[Non-Recoverable Advances: Unveiling a Rationale for a Key Decision](#)
[Excess Cash Allocations: Probing Advances on Positive Cashflowing Loans](#)
[Release Prices: Cherry Picking Across Office Portfolios, Sometimes at a Discount](#)
[Mezz Loan Sales: A Potential Headache for CMBS Workouts](#)
[Equity Pledges: Hotel Bossert Spotlights Dual Collateralized Loans](#)
[The Road to Conversion: Consider Office Ground Leases and ARD Loans](#)
[Credit 2023: Advancing and Workout Approaches to Play a Central Role](#)
[Hotel Receiverships: Palmer House Hilton Spotlights Stabilization Efforts](#)
[Office Modifications: 285 Madison May Offer a Blueprint for More to Come](#)
[Triple-A Shortfalls: Destiny Spotlights Delayed ASERs Impact](#)
[Inflation-Resistant Leases: Rent Steps Offer Some Revenue Protection, though Not Much](#)
[Industrial Delinquencies: Don't Happen Often, but Watch Closely When They Do](#)
[Hotel Reserves: Key Performance Driver after Pandemic-Driven Depletion](#)
[Government Tenants: Short Termination Notices and Specialized Properties](#)
[Mall Foreclosures: What to Track as Servicers May Shift Away from Modifications](#)

Disclaimer

Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. We have relied upon and assumed without independent verification, the accuracy and completeness of all information available from public sources.

Views and opinions expressed are for informational purposes only and do not constitute a recommendation by Academy Securities for any purpose including buying, selling, or holding any security. Views and opinions are current as of the date of this presentation and may be subject to change, they should not be construed as investment advice.

This information discusses general market activity, industry or sector trends, or other broad-based business, economic, market or political conditions and should not be construed as operational, research or investment advice. This material has been prepared by Academy Securities and is not financial research nor a product of Academy Securities. It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Academy Securities. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Academy Securities has no obligation to provide any updates or changes.

Economic and market forecasts presented herein reflect a series of assumptions and judgments as of the date of this presentation and are subject to change without notice. These forecasts do not take into account the specific investment objectives, restrictions, tax and financial situation or other needs of any specific client. Actual data will vary and may not be reflected here. These forecasts are subject to high levels of uncertainty that may affect actual performance. Accordingly, these forecasts should be viewed as merely representative of a broad range of possible outcomes. These forecasts are estimated, based on assumptions, and are subject to significant revision and may change materially as economic and market conditions change. Academy Securities has no obligation to provide updates or changes to these forecasts. Case studies and examples are for illustrative purposes only.

Index Benchmarks

Indices are unmanaged. The figures for the index reflect the reinvestment of all income or dividends, as applicable, but do not reflect the deduction of any fees or expenses which would reduce returns. Investors cannot invest directly in indices.

The indices referenced herein have been selected because they are well known, easily recognized by investors, and reflect those indices that the Investment Manager believes, in part based on industry practice, provide a suitable benchmark against which to evaluate the investment or broader market described herein. The exclusion of “failed” or closed hedge funds may mean that each index overstates the performance of hedge funds generally.

THIS MATERIAL DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.

©Academy Securities, Inc.